A NEW DAWN
IN DISEASE EARLY INTERCEPTION
Featured
This new investment will be used primarily to fund the development and commercialization of MiRXES’ pipeline of multi-cancer early detection tests that look for blood borne microRNA and other molecular signatures released by cancer and immune cells. The funds will also be used to accelerate regulatory approval and adoption of GASTROClear in China, Japan, selected countries in Asia, Europe and Americas that have high rates of gastric cancer.
In this ongoing Team Talk Series, we speak to Lihan, CEO and Co-founder of MiRXES, who has led the company in its journey from a humble startup back in 2014 to a global leader in microRNA-powered diagnostics today.
Learn more about the history and the work culture of MiRXES as well as how we took the opportunity expand our capabilities during COVID-19.
Follow our comic series to journey with PI Rxes to learn more about how we can harness the power and potential of microRNA.
Our Science & Pipeline
At MiRXES, we harness the power of RNA to deliver early, actionable and personalised diagnoses across the care continuum to improve and save lives. Prevention is better than cure.
With early detection, mitigating risk factors and implementing prevention strategies, most cancer deaths can be prevented.
Our science opens us to a world without late-stage cancer diagnoses. This is how we improve and save lives.
MiRXES endeavours to be at the forefront of disease early detection and interception.
Delivering Our Solutions
One in four people has cancer in the world today. At MiRXES, we know the importance of science in the fight against cancer.
We understand that to make the most impact in improving and saving lives, we must translate and deliver our innovative solutions from the lab to clinic.
Read more about how our solutions that range from industry-leading discovery tools and services to diagnostic tests for cancer, cardiovascular, metabolic and infectious diseases, and precision oncology can enable you to act sooner – when it matters most.
SOCIAL MEDIA
